Table 2 Adjusted hazard ratios for recurrence-free and overall survival by RCC subtypes in metastasis-naive patients (adjusted for T and N stage).

From: Comparative analysis of oncologic outcomes in surgically treated patients with renal cell carcinoma and renal vein thrombosis by pathologic subtypes

Metastasis-naive RCC (n = 503)

 

RFS

OS

HR

95% CI

p-value

HR

95% CI

p-value

Pathologic subtypes

Clear cell

RCC (n = 435)

Reference

Reference

 

Papillary RCC (n = 27)

1.112

0.688–1.798

0.664

1.632

0.937–2.844

0.083

 

Chromophobe RCC (n = 15)

0.963

0.493–1.880

0.913

1.270

0.621–2.599

0.512

 

Rare RCC (n = 26)

1.635

1.028–2.600

0.038

1.816

1.030–3.201

0.039

Pathologic

T stage

pT3a (n = 318)

Reference

Reference

 

pT3b (n = 134)

1.378

1.048–1.812

0.022

1.379

1.012–1.880

0.042

 

pT3c (n = 26)

2.089

1.285–3.396

0.003

2.072

1.080–3.973

0.028

 

pT4 (n = 25)

1.839

1.138–2.972

0.013

2.284

1.359–3.838

0.002

Pathologic

N stage

pN0 (n = 123)

Reference

Reference

 

pN1 (n = 65)

2.442

1.671–3.568

 < 0.001

1.764

1.128–2.760

0.013

 

pNx (n = 315)

1.123

0.841–1.499

0.429

0.992

0.703–1.399

0.964

  1. RFS, Recurrence-free Survival; OS, Overall Survival; RCC, Renal Cell Carcinoma; HR, Hazard Ratio; CI, Confidence Interval (95%).
Back to article page